Abstract
The aim of this study was to explore the effects of bone marrow mesenchymal stem cells (BMMSCs) and alendronate sodium (ALN) intervention on osteoporosis (OP). Sixty-eight 6-month-old healthy female Sprague Dawley (SD) rats were used to generate an OP model by removal of the ovaries. After 12 weeks, rats were treated with BMMSCs (BMMSC group) or ALN (ALN group) for 5 weeks. Serum type I collagen C terminal peptide (CTX_1), procollagen type I N-terminal propeptide (PINP), and bone alkaline phosphatase (BALP) were tested along with the femur bone density and other properties, including bone mineral density (BMD), BALP, percent trabecular area (BV/TV), trabecular thickness (Tb.Th), trabecular number (TbN), maximum load, maximum stress, maximum strain, and elastic modulus. BMD, BALP, BV/TV, Tb.Th, TbN, maximum load, maximum stress, maximum strain, and elastic modulus values were higher in the BMMSC group versus the ALN group relative to the control group (p < 0.05); CTX_1, PINP, trabecular separation (Tb.Sp), and osteoclast number (OC.N) were lowest in the BMMSC group versus the ALN group relative to the control group (p < 0.05). Both BMMSCs and ALN could improve the metabolic function and bone quality in osteoporotic mice while restoring the strength and toughness of bones. The intervention effects of BMMSCs are better than ALN in this model.
Acknowledgment
This study was supported by the Science and Technology Development Plan of Jilin Province, China (20110492).
Author statement
Research funding: Authors state no funding involved.
Conflict of interest statement: The authors declare no conflicts of interest.
Informed consent: Informed consent is not applicable.
Ethical approval: The conducted research is not related to either human or animals use.
References
[1] Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23–57.10.1007/s00198-012-2074-ySearch in Google Scholar PubMed PubMed Central
[2] Lazar A, Pacurar M, Campian RS. Bisphosphonates in bone diseases treatment. Rev Chimi Bucharest 2017;68:246–9.10.37358/RC.17.2.5429Search in Google Scholar
[3] Abdelazim IA, Faza MA, Ayash HM. Effects of raloxifene hydrochloride on bone mineral density and serum lipids in Kuwaiti postmenopausal women with osteoporosis. Arch Osteoporos 2015;4:1–5.10.4103/2278-960X.153518Search in Google Scholar
[4] Bhandari KH, Asghar W, Newa M, Jamali F, Doschak MR. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis. Curr Drug Deliv 2015;12:98–107.10.2174/156720181201150310154026Search in Google Scholar PubMed
[5] Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T. Treatment responses with once-weekly teriparatide therapy for osteoporosis. Osteoporos Int 2016;27:3057–62.10.1007/s00198-016-3640-5Search in Google Scholar PubMed PubMed Central
[6] Ummarino D. Osteoporosis: Romosozumab versus teriparatide. Nat Rev Rheumatol 2017;13:512.10.1038/nrrheum.2017.135Search in Google Scholar PubMed
[7] Rivadeneira F, Mäkitie O. Osteoporosis and bone mass disorders: from gene pathways to treatments. Trends Endocrinol Metab 2016;27:262–81.10.1016/j.tem.2016.03.006Search in Google Scholar PubMed
[8] MafiGolchin M, Heidari L, Ghaderian SM, Akhavan-Niaki H. Osteoporosis: a silent disease with complex genetic contribution. J Genet Genomics 2016;43:49–61.10.1016/j.jgg.2015.12.001Search in Google Scholar PubMed
[9] Cho SW, Sun HJ, Yang JY, Jung JY, An JH, Cho HY, et al. Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther 2009;17:1979–87.10.1038/mt.2009.153Search in Google Scholar PubMed PubMed Central
[10] Rodríguez JP, Ríos S, Fernández M, Santibañez JF. Differential activation of ERK1,2 MAP kinase signaling pathway in mesenchymal stem cell from control and osteoporotic postmenopausal women. J Cell Biochem 2004;92:745–54.10.1002/jcb.20119Search in Google Scholar PubMed
[11] Wang Z, Goh J, Das De S, Ge Z, Ouyang H, Chong JS, et al. Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 2006;12: 1753–61.10.1089/ten.2006.12.1753Search in Google Scholar PubMed
[12] Shen J, Tsai YT, Dimarco NM, Long MA, Sun X, Tang L. Transplantation of mesenchymal stem cells from young donors delays aging in mice. Sci Rep 2011;1:67.10.1038/srep00067Search in Google Scholar PubMed PubMed Central
[13] Ocarino Nde M, Boeloni JN, Jorgetti V, Gomes DA, Goes AM, Serakides R. Intra-bone marrow injection of mesenchymal stem cells improves the femur bone mass of osteoporotic female rats. Connect Tissue Res 2010;51:426–33.10.3109/03008201003597049Search in Google Scholar PubMed
[14] Lien CY, Chih-Yuan Ho K, Lee OK, Blunn GW, Su Y. Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells. J Bone Miner Res 2009;24:837–48.10.1359/jbmr.081257Search in Google Scholar PubMed
[15] Sun LY, Hsieh DK, Yu TC, Chiu HT, Lu SF, Luo GH, et al. Effect of pulsed electromagnetic field on the proliferation and differentiation potential of human bone marrow mesenchymal stem cells. Bioelectromagnetics 2009;30:251–60.10.1002/bem.20472Search in Google Scholar PubMed
[16] Wang Y, Li ZW, Luo M, Li YJ, Zhang KQ. Biological conduits combining bone marrow mesenchymal stem cells and extracellular matrix to treat long-segment sciatic nerve defects. Neural Regen Res 2015;10:965–71.10.4103/1673-5374.158362Search in Google Scholar PubMed PubMed Central
[17] Zhang ZJ, Li YJ, Liu XG, Huang FX, Liu TJ, Jiang DM, et al. Human umbilical cord blood stem cells and brain-derived neurotrophic factor for optic nerve injury: a biomechanical evaluation. Neural Regen Res 2015;10:1134–8.10.4103/1673-5374.160110Search in Google Scholar PubMed PubMed Central
[18] Herrmann M, Seibol MJ. The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta 2008;393:57–75.10.1016/j.cca.2008.03.020Search in Google Scholar PubMed
[19] Rotteveel J, Schoute E, Delemarre-van de Waal HA. Serum procollagen I carboxyterminal propeptide (PICP) levels through puberty: relation to height velocity and serum hormone levels. Acta Pediatr 1997;86:143–7.10.1111/j.1651-2227.1997.tb08855.xSearch in Google Scholar PubMed
[20] Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850–6.10.1200/JCO.20.3.850Search in Google Scholar PubMed
[21] Kulak CA, Dempster DW. Bone histomorphometry: a concise review for endocrinologists and clinicians. Arq Bras Endocrinol Metabol 2010;54:87–98.10.1590/S0004-27302010000200002Search in Google Scholar PubMed
[22] Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475–80.10.1172/JCI119668Search in Google Scholar
[23] Oxlund H, Barckman M, Ortoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 1995;17:365S–71S.10.1016/8756-3282(95)00328-BSearch in Google Scholar PubMed
[24] Lees S, Eyre DR, Barnard SM. BAPN dose dependence of mature crosslinking in bone matrix collagen of rabbit compact bone: corresponding variation of sonic velocity and equatorial diffraction spacing. Connect Tissue Res 1990;24:95–105.10.3109/03008209009152426Search in Google Scholar PubMed
[25] Mafi Golchin M, Heidari L, Ghaderian SM, Akhavan-Niaki H. Osteoporosis: a silent disease with complex genetic contribution. J Genet Genomics 2016;43:49–61.10.1016/j.jgg.2015.12.001Search in Google Scholar PubMed
[26] Kumar S, Wan C, Ramaswamy G, Clemens TL, Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Mol Ther 2010;18:1026–34.10.1038/mt.2009.315Search in Google Scholar PubMed PubMed Central
©2019 Walter de Gruyter GmbH, Berlin/Boston
